{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:46Z","timestamp":1781585686963,"version":"3.54.5"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Rituximab is an anti\u2010CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The\n                    <jats:italic>FCGR2A<\/jats:italic>\n                    (rs1801274) and\n                    <jats:italic>FCGR3A<\/jats:italic>\n                    (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases. A clinical trial was performed including adults with glomerular diseases who required rituximab (NEFRTX; EudraCT: 2020\u2013000484\u201023). Patients received 1.0\u2009g or 0.5\u2009g of rituximab on day 1 (\u00b1 day 14); biochemical parameters and rituximab concentration were measured, and\n                    <jats:italic>FCGR2A<\/jats:italic>\n                    and\n                    <jats:italic>FCGR3A<\/jats:italic>\n                    variants were characterized. Clinical outcome was evaluated at 6 and 12\u2009months. 30 patients were included.\n                    <jats:italic>FCGR2A<\/jats:italic>\n                    (rs1801274) and\n                    <jats:italic>FCGR3A<\/jats:italic>\n                    (rs396991) variants did not show an effect on clinical response to rituximab. When the effect of the variant was corrected by rituximab exposure, the expression of the\n                    <jats:italic>FCGR2A<\/jats:italic>\n                    rs1801274\u2010A allele vs. no expression was related to a poorer response at month 6 (odds ratio 0.034; 95% confidence interval 0.002\u20130.725;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.030); this effect was not seen for\n                    <jats:italic>FCGR3A<\/jats:italic>\n                    . Additional studies involving larger cohorts are warranted to validate these findings.\n                  <\/jats:p>","DOI":"10.1002\/prp2.70261","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:30:52Z","timestamp":1779442252000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of\n                    <scp>\n                      <i>FCGR2A<\/i>\n                    <\/scp>\n                    and\n                    <scp>\n                      <i>FCGR3A<\/i>\n                    <\/scp>\n                    Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-0568","authenticated-orcid":false,"given":"Mar\u00eda","family":"Larrosa\u2010Garc\u00eda","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Service, Vall D'hebron Hospital Campus  Barcelona Spain"},{"name":"Vall D'hebron Institute of Research  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Agraz","family":"Pamplona","sequence":"additional","affiliation":[{"name":"Vall D'hebron Institute of Research  Barcelona Spain"},{"name":"Clinical Nephrology Service, Vall D'hebron Hospital Campus  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-8933","authenticated-orcid":false,"given":"Susana Rojo","family":"Tolosa","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Unit. Hospital Universitario Virgen de Las Nieves  Granada Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Jim\u00e9nez","family":"Morales","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Service Hospital Universitario Virgen de Las Nieves  Granada Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa Sanz","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Vall D'hebron Institute of Research  Barcelona Spain"},{"name":"Immunology Division, Vall D'hebron Barcelona Hospital Campus  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica Mart\u00ednez","family":"Gallo","sequence":"additional","affiliation":[{"name":"Vall D'hebron Institute of Research  Barcelona Spain"},{"name":"Immunology Division, Vall D'hebron Barcelona Hospital Campus  Barcelona Spain"},{"name":"Department of Cell Biology, Physiology and Immunology Autonomous University of Barcelona (UAB)  Bellaterra Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Colobran","sequence":"additional","affiliation":[{"name":"Vall D'hebron Institute of Research  Barcelona Spain"},{"name":"Immunology Division, Vall D'hebron Barcelona Hospital Campus  Barcelona Spain"},{"name":"Department of Cell Biology, Physiology and Immunology Autonomous University of Barcelona (UAB)  Bellaterra Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Genestal","family":"Vicente","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Service, Vall D'hebron Hospital Campus  Barcelona Spain"},{"name":"Vall D'hebron Institute of Research  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea Moreno","family":"Pena","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Service, Vall D'hebron Hospital Campus  Barcelona Spain"},{"name":"Vall D'hebron Institute of Research  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Paola Bury","family":"Mac\u00edas","sequence":"additional","affiliation":[{"name":"Vall D'hebron Institute of Research  Barcelona Spain"},{"name":"Clinical Nephrology Service, Vall D'hebron Hospital Campus  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Bruno Montoro","family":"Ronsano","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Service, Vall D'hebron Hospital Campus  Barcelona Spain"},{"name":"Vall D'hebron Institute of Research  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"e_1_2_10_2_1","article-title":"Mabthera (Rituximab)","author":"European Medicines Agency","year":"2023","journal-title":"Summary of Drug Characteristics"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365\u20103083.2000.00745.x"},{"key":"e_1_2_10_4_1","unstructured":"\u201cRituximab (Intravenous) Including Biosimilars: Drug Information \u201dn.d."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.008"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016040449"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs515"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.10.006"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42556"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018803587"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201004\u2010020057"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.926289"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00390"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.1.73\u201081.1995"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-070656"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.059"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1371479"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102013\u2010306958"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1341"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102012\u2010202435"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397\u2010023\u201000308\u20109"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-11-0941"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201001\u2010009480"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116655"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001353"},{"key":"e_1_2_10_29_1","volume-title":"Oviedo","author":"Larrosa\u2010Garc\u00eda M.","year":"2025"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.70261","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:20:43Z","timestamp":1781583643000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/prp2.70261"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70261","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70261"}}